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Sustainable and cost-eﬀ ective monitoring of patients on ART
Decision -makers in resource-limited settings, particu-
larly in African countries hardest hit by the HIV epi-
demic, have to make diﬃ  cult choices about the best 
way to spend their restricted resources on HIV care and 
prevention in the present economic climate. One such 
important policy decision is how to monitor the huge 
numbers of patients on antiretroviral therapy (ART) 
cost-eﬀ ectively and sustainably.
In The Lancet Global Health, Daniel Keebler and col-
leagues1 present an economic analysis consisting of 
three mathematical models to assess the costs and 
beneﬁ ts of diﬀ erent strategies of clinical, CD4, and 
viral load monitoring for HIV-infected individuals 
on ART in three African countries with varying ART 
coverage and economies.
Key strengths of this work are that independently 
developed and validated models have been run on the 
same strategies with the same costs, allowing results 
to be compared.1 Results show that, in most scenarios, 
viral load monitoring every 6 months or 12 months 
is not cost-eﬀ ective,1 even when eﬀ ects on onward 
transmission and resistance are included, compared 
with the health beneﬁ ts of expanding ART coverage 
at the WHO 2010 CD4 threshold for ART initiation 
of 350 cells per μL, and even at the new proposed 
WHO 2013 threshold of 500 cells per μL.2 The authors 
conclude that viral load monitoring should only be 
considered in countries where ART rollout has been 
achieved with close to full coverage. 
The 2013 consolidated WHO guidelines2 make 
several notable recommendations, including: to move 
towards use of viral load monitoring, to increase the 
CD4 threshold for ART initiation to 500 cells per μL, 
and to use the Option B+ strategy for prevention of 
mother-to-child transmission (pMTCT) in generalised 
epidemics (starting ART for life in all HIV-infected 
pregnant women, regardless of CD4 count). The ﬁ rst 
two recommendations are aspirational and do not 
have supporting evidence from clinical trials.3–5 The 
third is largely based on programmatic considerations. 
Together, they would expand the numbers of adults 
needing ART from 16·7 million to 25·9 million (current 
coverage is 10 million).6 Therefore, priorities need to 
be set in the context of prevailing resource constraints. 
Appropriately framed economic studies, such as Keebler 
and colleagues’ report,1 are valuable for decision-makers 
facing this task.
The goals of monitoring at the individual level are 
to measure ART adherence (viral load), to guide the 
timing of switching to second-line ART to avoid severe 
clinical outcomes and preserve the ability to respond 
well to second-line ART, and to prevent onward HIV 
transmission7 (including resistant virus). Clinical, viral 
load, and CD4 failure can be deﬁ ned with diﬀ erent 
thresholds and, unsurprisingly, do not always correlate 
well. CD4 is a better predictor of imminent clinical 
progression than viral load and is best used to guide 
ART initiation.2 Viral load failure on ART occurs earliest 
and needs to be distinguished from temporary non-
adherence; one aim of viral load monitoring is to switch 
earlier, well before immunological or clinical failure 
occur. However, this critically requires that drugs are 
available for second-line treatment and beyond. Clinical 
monitoring alone is very eﬀ ective and low cost,1,8 but 
it will not perfectly predict CD4 or viral load failure, 
and switching might also occur unnecessarily—ie, with 
undetectable viral load.9 This is the principle behind 
targeted monitoring, whereby CD4 or viral load, or both, 
are used to prevent switching in case of poor speciﬁ city 
of clinical failure diagnosis.10
The WHO 2013 guidelines aspire to bring together 
treatment and prevention in both its earlier ART initiation 
and viral load monitoring guidance, and also to decrease 
the gap between well resourced and resource-poor 
settings. Although this goal is laudable, the importance 
of equity must be highlighted, since prioritising viral 
load monitoring over ART rollout would be likely to 
lead to more unequal health outcomes, as discussed in 
Keebler and colleagues’ report.1 The scarcity in capacity for 
laboratory monitoring must not be a barrier to providing 
ART to those in most need, nor to switching clinically 
failing sick patients, as endorsed by WHO.2
The Option B+ pMTCT strategy will require that 
ART availability is expanded and rolled out to low-
level health facilities in which pMTCT programmes 
are already operating in many African countries. This 
availability will be a good thing for patients who will 
not be required to travel so far to obtain drugs, and 
will hopefully reduce loss to follow-up.11 However, 
Option B+ will very probably increase costs and make 
Published Online
December 10, 2013
http://dx.doi.org/10.1016/
S2214-109X(13)70081-0
See Articles page e35
Copyright © Gibb et al. Open 
 access under CC BY-NC-ND license.
Comment
e5 www.thelancet.com/lancetgh   Vol 2   January 2014
the WHO 2013 monitoring recommendation even 
more challenging, since most health facilities in 
Africa are missing many basic commodities, let alone 
the capacity to manage viral load monitoring. Of 
58 health facilities surveyed across Malawi, Uganda, 
and Zimbabwe in 2012, only two of those providing 
ART provided viral load monitoring (both tertiary 
facilities). This number compared with CD4 testing 
in about a third of mainly secondary and tertiary 
facilities, with a further half sending samples oﬀ -site 
for CD4 testing.12
CD4 monitoring, especially with simpler machines 
(eg, Alere Pima CD4) and point-of-care tests that are 
currently being ﬁ eld tested in Africa, will undoubtedly 
save some lives by ensuring earlier switching than 
that with clinical monitoring alone.8 Viral load 
remains mostly unaﬀ ordable and point-of-care tests 
are not likely to become available in the near future. 
Since CD4 also identiﬁ es individuals most in need of 
immediate ART and other prophylaxis, caution should 
be applied before recommending doing away with it. 
As suggested by Keebler and colleagues,1 the continued 
implementation of CD4 monitoring is more likely to be 
cost-eﬀ ective in many settings than would be a rapid 
transition to viral load monitoring, although this must 
also be assessed against other competing priorities.
In conclusion, the authors and WHO should be con-
gratulated for this work. Although not included in 
the main WHO 2013 guidelines document, it provides 
important guidance for policy-makers in resource-
limited countries as they choose between competing 
priorities, and decide how to apply the new guidelines 
in their own settings.
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